Qiagen upgraded by Morgan Stanley with a new price target
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Morgan Stanley upgraded Qiagen from Equal-Weight to Overweight and set a new price target of $42.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2026 | $42.00 | Equal-Weight → Overweight | Morgan Stanley |
| 4/29/2026 | $43.00 | Neutral → Outperform | Robert W. Baird |
| 4/14/2026 | $44.00 | Overweight → Equal Weight | Barclays |
| 3/13/2026 | $54.00 | Hold → Buy | Deutsche Bank |
| 1/22/2026 | $54.00 | Buy → Hold | Deutsche Bank |
| 12/11/2025 | $50.00 | Buy → Neutral | Citigroup |
| 6/24/2025 | $55.00 | Overweight | Barclays |
| 4/4/2025 | Buy → Neutral | Redburn Atlantic |
Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem New software capabilities support standardized analysis and reporting across digital PCR workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across li
Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN's broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts
New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN's digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and man
Morgan Stanley upgraded Qiagen from Equal-Weight to Overweight and set a new price target of $42.00
Robert W. Baird upgraded Qiagen from Neutral to Outperform and set a new price target of $43.00
Barclays downgraded Qiagen from Overweight to Equal Weight and set a new price target of $44.00
SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
20-F - QIAGEN N.V. (0001015820) (Filer)
IRANNOTICE - QIAGEN N.V. (0001015820) (Filer)
Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been app
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board. "We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Ma
Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS QIAGEN delivers well ahead of schedule on its commitment to return at least $1 billion through end-2028, considering additional ways to increase returns in 2026 and beyond QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment
Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem New software capabilities support standardized analysis and reporting across digital PCR workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across li
Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN's broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts
New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN's digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and man
SC 13G - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)